Literature DB >> 31786775

Anti-inflammatory Effect of AZD6244 on Acrolein-Induced Neuroinflammation.

Wen-Chien Ho1, Chia-Chi Hsu2, Hui-Ju Huang3, Hsiang-Tsui Wang4, Anya Maan-Yuh Lin5,6,7.   

Abstract

Clinically, high levels of acrolein (a highly reactive α, β-unsaturated aldehyde) and acrolein adducts are detected in the brain of patients with CNS neurodegenerative diseases, including Alzheimer's disease and spinal cord injury. Our previous study supports this notion by showing acrolein as a neurotoxin in a Parkinsonian animal model. In the present study, the effect of AZD6244 (an ATP non-competitive MEK1/2 inhibitor) on acrolein-induced neuroinflammation was investigated using BV-2 cells and primary cultured microglia. Our immunostaining study showed that lipopolysaccharide (LPS, an inflammation inducer as a positive control) increased co-localized immunoreactivities of phosphorylated ERK and ED-1 (a biomarker of activated microglia) in the treated BV-2 cells. Similar elevation in co-localized immunoreactivities of phosphorylated ERK and ED-1 was detected in the acrolein-treated BV-2 cells. Furthermore, Western blot assay showed increases in phosphorylated ERK in BV-2 cells subjected to LPS (1 μg/mL) or acrolein (30 μM); these increases were blocked by AZD6244 (10 μM). At the same time, AZD6244 attenuated LPS-induced TNF-α (a pro-inflammatory cytokine) and cyclooxygenase-II (COX II, a pro-inflammatory enzyme). Consistently, AZD6244 reduced acrolein-induced elevations in COX-II mRNA and COX-II protein expression. In addition, AZD6244 inhibited acrolein-induced increases in activated caspase 1 (a biomarker of inflammasome activation) and heme oxygenase-1 (a redox-regulated chaperone protein) in BV-2 cells. Using a transwell migration assay, AZD6244 attenuated acrolein (5 μM)-induced migration of BV-2 cells and primary cultured microglia. In conclusion, our study shows that acrolein is capable of inducing neuroinflammation which involved ERK activation in microglia. Furthermore, AZD6244 is capable of inhibiting acrolein-induced neuroinflammation. Our study suggests that ERK inhibition may be a neuroprotective target against acrolein-induced neuroinflammation in the CNS neurodegenerative diseases.

Entities:  

Keywords:  AZD6244; Acrolein; BV-2 cells; ERK pathway; Neuroinflammation

Year:  2019        PMID: 31786775     DOI: 10.1007/s12035-019-01758-8

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  4 in total

1.  Neuronal activity regulated pentraxin (narp) and GluA4 subunit of AMPA receptor may be targets for fluoxetine modulation.

Authors:  Isabella A Heinrich; Andiara E Freitas; Ingrid A V Wolin; Ana Paula M Nascimento; Roger Walz; Ana Lúcia S Rodrigues; Rodrigo B Leal
Journal:  Metab Brain Dis       Date:  2021-02-02       Impact factor: 3.584

2.  MEK1/2 Inhibitor (GDC0623) Promotes Osteogenic Differentiation of Primary Osteoblasts Inhibited by IL-1β through the MEK-Erk1/2 and Jak/Stat3 Pathways.

Authors:  Zeng-Qiao Zhang; Xiao-Shen Hu; Ye-Chen Lu; Jun-Peng Zhang; Wen-Yao Li; Wei-Yang Zhang; Wei Feng; Dao-Fang Ding; Jian-Guang Xu
Journal:  Int J Endocrinol       Date:  2021-12-22       Impact factor: 3.257

3.  Pharmacological Inhibition of Spermine Oxidase Suppresses Excitotoxicity Induced Neuroinflammation in Mouse Retina.

Authors:  Moaddey Alfarhan; Fang Liu; Shengshuai Shan; Prahalathan Pichavaram; Payaningal R Somanath; S Priya Narayanan
Journal:  Int J Mol Sci       Date:  2022-02-15       Impact factor: 5.923

4.  Selumetinib - a potential small molecule inhibitor for osteoarthritis treatment.

Authors:  Xiaohang Zheng; Jianxin Qiu; Wenjun Pan; Yuhang Gong; Weikang Zhang; Ting Jiang; Lihua Chen; Weifu Chen; Zhenghua Hong
Journal:  Front Pharmacol       Date:  2022-09-27       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.